M Singh

Summary

Affiliation: Chiron Corporation
Country: USA

Publications

  1. pmc Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine
    M Singh
    United Biomedical, Inc, Hauppauge, New York 11788, USA
    Infect Immun 65:1716-21. 1997
  2. ncbi request reprint A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2
    M Singh
    Adjuvant Research Division, Chiron Corporation, Emeryville, CA 94608, USA
    Vaccine 16:1822-7. 1998
  3. ncbi request reprint Controlled release of recombinant insulin-like growth factor from a novel formulation of polylactide-co-glycolide microparticles
    M Singh
    Chiron Corporation, 4560 Horton Street, Emeryville, CA 94608, USA
    J Control Release 70:21-8. 2001
  4. ncbi request reprint Advances in vaccine adjuvants
    M Singh
    Chiron Corporation, 5300 Chiron Way, Emeryville, CA 94608, USA
    Nat Biotechnol 17:1075-81. 1999
  5. ncbi request reprint Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1
    D T O'Hagan
    Chiron Corporation, 4560 Horton Street, Emeryville, CA 94608, USA
    Vaccine 18:1793-801. 2000
  6. ncbi request reprint Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen
    D T O'Hagan
    Chiron Corporation, 4560 Horton Street, Emeryville, CA 94608, USA
    Vaccine 20:3389-98. 2002
  7. ncbi request reprint Mucosal immunization with HIV-1 gag DNA on cationic microparticles prolongs gene expression and enhances local and systemic immunity
    M Singh
    Chiron Corporation, Immunology and Infectious Diseases, 4560 Horton Street, Emeryville, California, CA 94563, USA
    Vaccine 20:594-602. 2001
  8. ncbi request reprint The encapsulation of a model protein in poly (D, L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility
    J P McGee
    United Biomedical, Inc, Hauppauge, NY 11788, USA
    J Microencapsul 14:197-210. 1997
  9. ncbi request reprint A novel bioadhesive intranasal delivery system for inactivated influenza vaccines
    M Singh
    Chiron Technologies, Chiron Corporation, 4560 Horton Street, Emeryville, CA 94608, USA
    J Control Release 70:267-76. 2001
  10. pmc Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines
    D O'Hagan
    Vaccines Research, Chiron Corporation, Emeryville, California 94608, USA
    J Virol 75:9037-43. 2001

Detail Information

Publications11

  1. pmc Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine
    M Singh
    United Biomedical, Inc, Hauppauge, New York 11788, USA
    Infect Immun 65:1716-21. 1997
    ..An intradermal-challenge study was also performed with rabbits, which showed similar levels of protection in sera from alum- and microparticle-immunized animals at 4, 12, and 32 weeks after immunization...
  2. ncbi request reprint A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2
    M Singh
    Adjuvant Research Division, Chiron Corporation, Emeryville, CA 94608, USA
    Vaccine 16:1822-7. 1998
    ..The MF59 induced higher levels of serum IL-4 and IL-5 cytokines, suggesting a more Th2 type of response...
  3. ncbi request reprint Controlled release of recombinant insulin-like growth factor from a novel formulation of polylactide-co-glycolide microparticles
    M Singh
    Chiron Corporation, 4560 Horton Street, Emeryville, CA 94608, USA
    J Control Release 70:21-8. 2001
    ..PLG microparticles with entrapped rhIGF-I are a promising delivery system which may allow rhIGF-I to be used for a broad range of therapeutic indications...
  4. ncbi request reprint Advances in vaccine adjuvants
    M Singh
    Chiron Corporation, 5300 Chiron Way, Emeryville, CA 94608, USA
    Nat Biotechnol 17:1075-81. 1999
    ..Ultimately, the development of more potent adjuvants may allow vaccines to be used as therapeutic, rather than prophylactic, agents...
  5. ncbi request reprint Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1
    D T O'Hagan
    Chiron Corporation, 4560 Horton Street, Emeryville, CA 94608, USA
    Vaccine 18:1793-801. 2000
    ..In contrast to the observations with gp120, immunization in baboons with PLG/p24 in MF59 induced significantly enhanced antibody responses after boosting, in comparison to immunization with MF59 alone + p24...
  6. ncbi request reprint Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen
    D T O'Hagan
    Chiron Corporation, 4560 Horton Street, Emeryville, CA 94608, USA
    Vaccine 20:3389-98. 2002
    ..To support this hypothesis, preliminary in vitro studies were undertaken to show upregulation of CD86 on mouse bone marrow-derived dendritic cells (BMDC) in vitro, following incubation with CpG formulations...
  7. ncbi request reprint Mucosal immunization with HIV-1 gag DNA on cationic microparticles prolongs gene expression and enhances local and systemic immunity
    M Singh
    Chiron Corporation, Immunology and Infectious Diseases, 4560 Horton Street, Emeryville, California, CA 94563, USA
    Vaccine 20:594-602. 2001
    ..IN immunizations with PLG-DNA, but not naked DNA, induced prolonged expression of gag protein in local and systemic lymphoid tissues. These data have important implications for DNA vaccine development...
  8. ncbi request reprint The encapsulation of a model protein in poly (D, L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility
    J P McGee
    United Biomedical, Inc, Hauppauge, NY 11788, USA
    J Microencapsul 14:197-210. 1997
    ..The results demonstrated that the preparation method was both robust and reproducible and allowed the preparation of microparticles with desired characteristics in terms of loading levels, particle size and release rates...
  9. ncbi request reprint A novel bioadhesive intranasal delivery system for inactivated influenza vaccines
    M Singh
    Chiron Technologies, Chiron Corporation, 4560 Horton Street, Emeryville, CA 94608, USA
    J Control Release 70:267-76. 2001
    ..05)...
  10. pmc Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines
    D O'Hagan
    Vaccines Research, Chiron Corporation, Emeryville, California 94608, USA
    J Virol 75:9037-43. 2001
    ..Therefore, formulation of DNA vaccines by adsorption onto PLG microparticles is a powerful means of increasing vaccine potency...
  11. ncbi request reprint Recent developments in adjuvants for vaccines against infectious diseases
    D T O'Hagan
    Chiron Corporation, Immunology and Infectious Diseases, 4560 Horton Street, Emeryville, CA 94608, USA
    Biomol Eng 18:69-85. 2001
    ..The discovery of more potent adjuvants may allow the development of vaccines against infectious agents such as HIV which do not naturally elicit protective immunity. New adjuvants may also allow vaccines to be delivered mucosally...